Cipla to freeze increments of around 400 top managers: Report

29 Sep 2016 Evaluate

Cipla, one of India’s leading generic pharmaceutical companies has reportedly decided to reduce its ballooning employee cost by freezing increments of 300-400 of its top managers as part of the company’s operational revamp.  In the past five years, the company has been a laggard among its peers as management and operational changes dragged the company’s profits down. For the first quarter of FY17, the company’s employee cost rose by 11% to Rs 687 crore on a Y-o-Y basis, at a time when its profits had declined by 43% to Rs 365 crore.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.

Cipla Share Price

1434.60 0.00 (0.00%)
14-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1700.55
Dr. Reddys Lab 1186.45
Cipla 1434.60
Zydus Lifesciences 884.00
Lupin 2195.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×